Caris Life Sciences (CAI) Earnings: Q3 2026 Results

The quarter ended September 30, 2026 and Caris Life Sciences published the results on November 4, 2026. Revenue and diluted EPS are shown against Q3 2025, the same quarter a year earlier, which takes seasonal swings out of the comparison.

• Caris Life Sciences reports in thousands of dollars; figures here are converted to millions. It went public in June 2025, so per-share figures for quarters before then were computed on a much smaller common share count and are not comparable.

Source: Caris Life Sciences Q3 2026 results, November 4, 2026. Also in the Form 10-Q for the quarter ended September 30, 2026. Figures as reported; checked against the release on November 10, 2026.

How Caris Life Sciences splits revenue in its own release, under its own labels, for Q3 2026 against Q3 2025. Indented lines are parts of the line above them.

• Caris Life Sciences's Molecular profiling services revenue was $263 million in Q3 2026, up 27% from $208 million in Q3 2025, 95% of total revenue.
• Caris Life Sciences's Pharma research and development services revenue was $12.7 million in Q3 2026, up 37% from $9.2 million in Q3 2025, 5% of total revenue.

Segment lines are the figures writers cite most often, because they show where the growth in a quarter came from. Companies redraw their segments from time to time and restate the prior year to match, so a year-ago figure here can differ from the one printed a year ago. When that has happened, the note above says so.

From the earnings release

In its Q3 2026 release, Caris Life Sciences said:

“Caris Life Sciences now expects full year 2026 revenue to be in the range of $1.04 to $1.05 billion, representing growth of 28% to 29% compared to full year 2025 and reaffirms its guidance for clinical therapy selection volume growth of approximately 20% compared to full year 2025.”

Source: Caris Life Sciences Q3 2026 release, Nov 4, 2026.

This is the company's own guidance as of Nov 4, 2026, quoted as given. Walnut does not make forecasts of its own. Analyst estimates for the coming quarters are on the CAI forecast page.

Revenue and diluted EPS for the last 5 quarters. Each date links to that quarter's release.

GAAP total revenue and diluted net income (loss) per share attributable to common shareholders, each as first reported in that quarter's release. Caris reported a net loss per share of $0.00 for Q1 2026 and Q2 2026.

We do not hold a confirmed date for Caris Life Sciences's next report. Companies post the date on their investor relations site a few weeks ahead, usually with the time of the conference call.

Each quarter keeps its own page with the figures as reported, so a link to one stays pointed at the same numbers after the next report.

• Q3 2026 (this page), reported Nov 4, 2026

Caris Life Sciences earns almost all of its revenue from molecular profiling of tumors and blood for cancer patients: $262.7 million of $275.4 million total revenue in Q3 2026. The other $12.7 million came from pharma research and development services, work done for biopharma partners. (Caris Life Sciences Q3 2026 release, Nov 4, 2026; Caris Life Sciences Form 10-Q, Q3 2026, Nov 4, 2026)

Caris Life Sciences said molecular profiling services revenue rose 26.6% because of higher clinical case volume and higher reimbursement, including improved average selling prices from enhanced contracting and collection capabilities. It completed approximately 61,500 clinical cases in the quarter, against 50,800 a year earlier, consisting of over 358,000 total oncology tests. (Caris Life Sciences Form 10-Q, Q3 2026, Nov 4, 2026; Caris Life Sciences Q3 2026 release, Nov 4, 2026)

Medicare is the largest single source of payment. Revenue from clinical cases for patients covered by Medicare was approximately 36.9% of molecular profiling services revenue in Q3 2026, down from 39.4% a year earlier. The 10-Q names three major payers: Payer 1 accounted for 35.2% of revenue in the quarter, Payer 2 for 12.1% and Payer 3 for 13.9%. (Caris Life Sciences Form 10-Q, Q3 2026, Nov 4, 2026)

Pharma research and development services revenue rose to $12.7 million from $9.2 million, which Caris Life Sciences attributed to the timing of delivery under its agreements. Over nine months it fell to $29.5 million from $34.6 million. (Caris Life Sciences Form 10-Q, Q3 2026, Nov 4, 2026)

Caris Life Sciences earned GAAP net income of $15.3 million, or $0.05 per diluted share, in Q3 2026, against $24.3 million, or $0.08, a year earlier. Operating expenses rose 42% to $163.0 million on headcount-related costs, research and development and marketing, and gross margin slipped to 66% from 68%. Caris reports no adjusted EPS; its non-GAAP measures are Adjusted EBITDA and free cash flow. (Caris Life Sciences Q3 2026 release, Nov 4, 2026)

Adjusted EBITDA was $44.4 million, against $51.2 million a year earlier. The largest add-back in that measure was stock-based compensation expense of $18.5 million. Diluted weighted-average shares were 295,140,869. As of September 30, 2026 Caris had repurchased and retired 1,514,525 shares for $27.9 million, leaving $72.1 million under its $100.0 million program. (Caris Life Sciences Q3 2026 release, Nov 4, 2026; Caris Life Sciences Form 10-Q, Q3 2026, Nov 4, 2026)

Diluted EPS divides net income by the weighted average number of shares outstanding in the quarter, plus the shares that options and other equity awards could add. Buybacks shrink that count and lift EPS for the same profit; share issuance and stock awards enlarge it.

Caris Life Sciences gives a full-year outlook in its release. With Q3 2026 results it raised 2026 revenue guidance to $1.04 billion to $1.05 billion, growth of 28% to 29% over 2025, and reaffirmed clinical therapy selection volume growth of approximately 20%. It gives no quarterly or EPS guidance in the release. (Caris Life Sciences Q3 2026 release, Nov 4, 2026)

A consensus figure is the average of the models published by the analysts who cover Caris Life Sciences, collected by a data provider and revised up to the day of the report. A quarter that lands above it says how expectations were set as much as how the business did, and the share price on the day also reflects the guidance and the lines no consensus covers.

The consensus figures on this page are Yahoo Finance's, as pulled on the date shown. Each comes with the number of analysts behind it; the smaller that number, the more one revised estimate can move the average.

The figures below are the ones Caris Life Sciences's own release and filings put weight on for Q3 2026, with the latest reported value for each.

What the quarter means for a holding is a separate question from what it reported. The case for and against owning CAI is on is CAI a buy or a sell?, what analysts expect next is on the CAI forecast, and what the company does is on the Caris Life Sciences (CAI) stock page.

Every number on this page can be traced to a document Caris Life Sciences published. Checking one takes a couple of minutes, and it is worth doing before you quote a figure anywhere.

• The results release is the document linked in the source line above. Companies publish it on their investor relations site at the moment results go out, and it carries the headline tables: revenue, operating income, net income and EPS for the quarter and the year-ago quarter.
• The same release is filed with the SEC as Exhibit 99.1 to a Form 8-K under Item 2.02, usually on the day of the report. The SEC copy does not change after the fact, which makes it the safer thing to link when you cite a number.
• The quarterly report (Form 10-Q) follows within a few weeks and carries the full financial statements, the segment note and management's discussion of what changed. The fourth quarter is covered by the annual report (Form 10-K) instead.
• Restated comparisons are flagged in the notes on this page. When a company redraws its segments or changes how it adjusts EPS, it restates the year-ago column, so the year-ago figure in a new release can differ from the one printed a year ago. This page always uses the comparison in the newer release, because that is the like-for-like one.

A walk-through of every line in a release, with what each one tells you, is in how to read an earnings report.